ducovest

ESLOY:OTC-Essilor International SA (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 114.12

Change

+0.23 (+0.20)%

Market Cap

USD 106.82B

Volume

0.19M

Analyst Target

USD 54.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

Company Website : https://www.essilorluxottica.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+5.46 (+2.42%)

 USD 104.69B
HOCPY Hoya Corp

-1.31 (-0.96%)

 USD 46.93B
HOCPF HOYA Corporation

N/A

 USD 46.92B
CLPBF Coloplast A/S

-5.71 (-4.15%)

 USD 31.46B
CLPBY Coloplast A

-0.05 (-0.36%)

 USD 31.20B
TRUMF Terumo Corporation

-0.17 (-0.95%)

 USD 29.47B
SAUHF Straumann Holding AG

+8.96 (+6.19%)

 USD 23.15B
OCPNF Olympus Corporation

N/A

 USD 20.54B
SRTOY Sartorius Stedim Biotech S.A

+0.24 (+1.15%)

 USD 20.35B
SDMHF Sartorius Stedim Biotech S.A

+6.14 (+3.09%)

 USD 20.03B

ETFs Containing ESLOY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.56% 72% C 68% D+
Dividend Return 2.10% 72% C 36% F
Total Return 15.66% 69% C- 68% D+
Trailing 12 Months  
Capital Gain 22.71% 72% C 74% C
Dividend Return 2.27% 60% D- 33% F
Total Return 24.98% 72% C 73% C
Trailing 5 Years  
Capital Gain 57.39% 82% B 80% B-
Dividend Return 9.06% 47% F 31% F
Total Return 66.44% 84% B 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 13.03% 60% D- 58% F
Dividend Return 14.57% 61% D- 56% F
Total Return 1.54% 53% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 21.61% 87% B+ 84% B
Risk Adjusted Return 67.42% 96% N/A 93% A
Market Capitalization 106.82B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.